Replies to post #443555 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

DD, KnowFear and Bala have created a pure strawman argument.

No, I’ve argued with plenty of links and a video clip on UCLA clinical trial that beyond doubt mention the combo GBM trial with Keytruda and where ATL-DC is DCVax-L.

I’ve never mentioned any lung cancer trial.

Adam Feuerstein tried to sow doubt about DCVax-L being used in this trial and as I documented, didn’t succeed.

But I am glad you agree, that it is DCVax-L under the guise of the generic name ATL-DC, that is being used in the combo trial with Pembrolizumab, Keytruda.

[hoffmann6383]

the totality of your argument is nonsensical

[Dr Bala]

Simply nonsense.

[sentiment_stocks]

I was briefly catching up on today’s discussions on the board and from what I recalled, ex (welcome back, lol) was not questioning whether the vaccine in the UCLA recurrent GBM trial was DCVax-L or not, but was pointing to a combo trial they’re doing at UCLA with lung tumors.

The assertion I made yesterday was that UCLA has a combo trial using a dc vaccine and The assertion I made yesterday was that UCLA has a combo trial using a dc vaccine and Keytruda that is not related to DCVax-L.

It is this trial using a genetically engineered dc vaccine and Keytruda in lung cancer.

Regarding the UCLA trial, many here will remember that Linda Liau herself told me in person several years ago at a presentation she, and several other UCLA neurology staff members attended including P. Leia Nghiemphu, MD. It was a pretty small event, and I had a chance to talk with LL alone for about five minutes (she revealed nothing material to me… I think NWBO was writing the SAP at the time?); and I asked her if the autologous dendritic cell vaccine being used in the recurrent GBM trial was DCVax-L to which she replied yes. She said that because Northwest was not sponsoring the trial, nor making the vaccine (they had very little money), UCLA was making the vaccine themselves, which they could do at UCLA because of their relationship with the company and involvement with DCVax-L. Something like that. I also spoke with Dr. N for maybe ten minutes after the presentation who confirmed that it was indeed DCVax. To be clear, I told both doctors that I was an NWBO shareholder up front.

Ex knows all this, as well as the other evidence gathered, so I doubt he’s questioning if DCVax-L is the vaccine being used in the recurrent GBM trial any more.

Now… regarding that dendritic cell vaccine being used in a combo lung trial.

Color: back around maybe 2014?, my neighbor’s son (he was the valedictorian of his high school) was accepted into UCLA. He wanted to go into medicine. When he’d come home for a visit, I’d occasionally chat with him about what he was interested in pursuing there. He had said he was really interested in “immunotherapy”. Well of course, I asked if he’d met Dr Prins and Dr Liau. I told him all about DCVax-L and UCLA’s involvement.

Fast forward: he is now working under Dr Prins and a lung doctor and they are using DCVax-L in some lung studies. He told me this about a year ago, and referred to the vaccine UCLA was using as DCVax-L… for what that’s worth. I don’t see him that often, and when I do, it’s usually just a quick wave, and he hasn’t told me anything material; and we have not discussed anything related to the P3 trial.

[Know-Fear]

I was confirming your patent assertion. Made no claims about the UCLA combo trial I don’t have a dog in that fight. Certainly not making a strawman argument.

By the way welcome back too. I can understand taking a break. I’ve been posting less

[Dr Bala]

As long as you agree that the UCLA ATL-DC is DCVax-L, I don't have a problem with your other patent statements.